Gillen LP - Search Results

1

Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.

Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE. Veronese ML, et al. Among authors: gillen lp. J Clin Pharmacol. 2003 Aug;43(8):831-9. doi: 10.1177/0091270003256059. J Clin Pharmacol. 2003. PMID: 12953340 Clinical Trial.

2

Effect of mibefradil on CYP3A4 in vivo.

Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, Greenberg HE. Veronese ML, et al. Among authors: gillen lp. J Clin Pharmacol. 2003 Oct;43(10):1091-100. doi: 10.1177/0091270003256687. J Clin Pharmacol. 2003. PMID: 14517191 Clinical Trial.

3

Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.

Prueksaritanont T, Vega JM, Rogers JD, Gagliano K, Greenberg HE, Gillen L, Brucker MJ, McLoughlin D, Wong PH, Waldman SA. Prueksaritanont T, et al. J Clin Pharmacol. 2000 Nov;40(11):1274-9. J Clin Pharmacol. 2000. PMID: 11075313 Clinical Trial.

4

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA. Greenberg HE, et al. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1509-15. J Clin Pharmacol. 2000. PMID: 11185674 Clinical Trial.

5

Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.

Gharaibeh MN, Gillen LP, Osborne B, Schwartz JI, Waldman SA. Gharaibeh MN, et al. Among authors: gillen lp. J Clin Pharmacol. 1998 Jun;38(6):492-5. doi: 10.1002/j.1552-4604.1998.tb05785.x. J Clin Pharmacol. 1998. PMID: 9650537 Clinical Trial.

6

Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.

Waldman SA, Vitow C, Osborne B, Gillen L, Argentieri DC, Wong FA, Smith IL, Chow AT, Misiti J, Bjornsson TD. Waldman SA, et al. J Clin Pharmacol. 1996 May;36(5):462-8. doi: 10.1002/j.1552-4604.1996.tb05033.x. J Clin Pharmacol. 1996. PMID: 8739025 Clinical Trial.

7

Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.

McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S. McCrea J, et al. J Clin Pharmacol. 1999 Dec;39(12):1212-20. doi: 10.1177/00912709922012015. J Clin Pharmacol. 1999. PMID: 10586386 Clinical Trial.

8

Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers.

Greenberg HE, Wissel P, Barrett J, Barchowsky A, Gould R, Farrell D, Panebianco D, Hand E, Gillen L, Goldberg MR, Bjornsson TD. Greenberg HE, et al. J Clin Pharmacol. 2000 May;40(5):496-507. doi: 10.1177/00912700022009116. J Clin Pharmacol. 2000. PMID: 10806603 Clinical Trial.

9

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.

McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR. McCrea JB, et al. Clin Pharmacol Ther. 1999 Mar;65(3):348-52. doi: 10.1016/S0009-9236(99)70114-1. Clin Pharmacol Ther. 1999. PMID: 10096267 No abstract available.

10

Plasma elevations of histamine and a prostaglandin metabolite in acute asthma.

Skoner DP, Page R, Asman B, Gillen L, Fireman P. Skoner DP, et al. Am Rev Respir Dis. 1988 May;137(5):1009-14. doi: 10.1164/ajrccm/137.5.1009. Am Rev Respir Dis. 1988. PMID: 3195799

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters